Table 3 Clinical trials based on CAR-NK cell therapy for human hematological malignancies registered in ClinicalTrials.gov (May 2021)
From: CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Condition | Dose | Target Ag | Phase | Participant number | Location | NCT number |
|---|---|---|---|---|---|---|
Non-Hodgkin lymphoma (NHL) | 2 × 106 /kg 6 × 106 /kg 2 × 107/kg | CD19 | Early 1 | 9 | China | NCT04639739 |
B cell lymphoma (BCL) | 50 × 103 /kg 600 × 103 /kg | CD22 | Early 1 | 9 | China | NCT03692767 |
Non-Hodgkin lymphoma (NHL | N.A | CD19 | 1 | 25 | China | NCT04887012 |
B cell lymphoma (BCL) | 50 × 103 /kg 600 × 103 /kg | CD19 | Early 1 | 9 | China | NCT03690310 |
Multiple Myeloma (MM) | N.A | BCMA | 1/2 | 23 | China | NCT03940833 |
B cell lymphoma (BCL) | 50 × 103 /kg 600 × 103 /kg | CD19 CD22 | Early 1 | 10 | China | NCT03824964 |
Mantle cell lymphoma (MCL) Diffuse large B cell lymphoma (DLBCL) Non-Hodgkin lymphoma (NHL) Follicular lymphoma (FL) | N.A | CD19 | 1/2 | 0 | USA | NCT03579927 |